Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis

• Auteurs principaux: April W. Armstrong (Auteur), Sang Hee Park (Auteur), Vardhaman Patel (Auteur), Pierre Nicolas (Auteur), Wei-Jhih Wang (Auteur), Matthew J. Colombo (Auteur), Viktor Chirikov (Auteur)
• Format: Livre
• Publié: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Introduction Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate to severe plaque psoriasis in the POETYK PSO-1 and PSO-2 clinical trials. In the study reported here, we aimed to determine the overall 52-week cumulative clinical benefit of treatment initia...